Safety and Efficacy of YH14617 in Diabetes Mellitus

NCT01507038 on ClinicalTrials.gov · last registry update 2015-02-18

Finished January 2015, after enrolling 84 people. Primary outcome, as filed: Change from baseline in HbA1c at week 12. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Yuhan Corporation
Sponsor type: Industry
Enrollment: 84
Started: 2011-12
Primary completion: 2015-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline in HbA1c at week 12

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.